Clinical Trials Logo

Lymphoma, Follicular clinical trials

View clinical trials related to Lymphoma, Follicular.

Filter by:
  • Terminated  
  • « Prev · Page 11

NCT ID: NCT00019708 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Start date: June 1999
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of geldanamycin analogue in treating patients who have advanced solid tumors or non-Hodgkin's lymphoma. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00015912 Terminated - Clinical trials for Recurrent Grade 2 Follicular Lymphoma

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Start date: July 2001
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combining thalidomide with interferon alfa in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Interferon alfa may interfere with the growth of cancer cells. Combining thalidomide with interferon alfa may kill more tumor cells

NCT ID: NCT00012298 Terminated - Clinical trials for Recurrent Small Lymphocytic Lymphoma

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Start date: April 2001
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II trial to study the effectiveness of combining radiolabeled monoclonal antibody therapy and rituximab with and without filgrastim and interleukin-11 in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells. Biological therapies such as filgrastim and interleukin-11 use different ways to stimulate the immune system and stop cancer cells from growing.

NCT ID: NCT00005950 Terminated - Clinical trials for Recurrent Small Lymphocytic Lymphoma

506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma

Start date: April 2000
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or T-cell lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die

NCT ID: NCT00005786 Terminated - Clinical trials for Recurrent Small Lymphocytic Lymphoma

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

Start date: January 2001
Phase: N/A
Study type: Interventional

Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory lymphoma or leukemia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

NCT ID: NCT00003152 Terminated - Lymphoma Clinical Trials

Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Start date: March 1997
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and radiation therapy and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy followed by interferon alfa alone or combination chemotherapy plus radiation therapy and peripheral stem cell transplantation in treating patients who have previously untreated stage III or stage IV follicular non-Hodgkin's lymphoma.